다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Clinical neuropharmacology, v.37 no.1, 2014년, pp.6 - 8
Grosshans, Martin (*Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health Mannheim, University of Heidelberg) , Mutschler, Jochen (and †Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.) , Luderer, Mathias , Mann, Karl , Kiefer, Falk
OBJECTIVES: Sleep disorders are a widespread, persistent problem among alcohol-dependent patients and have been implicated in an increased risk for alcohol relapse. The melatonin-agonist agomelatine has been shown to improve overall sleep quality without daytime sedation. METHODS: In an off-label therapeutic setting, 9 alcohol-dependent patients with chronic sleep disorders received nightly doses of between 25 and 50 mg of agomelatine. RESULTS: After 6 weeks of agomelatine treatment, the Pittsburgh Sleep Quality Index global score for all patients had decreased significantly from a mean (SD) of 13.1 (1.7) to 7.8 (1.7) (t = 12.8; P = 0.00). CONCLUSIONS: Agomelatine is a preparation that is not prone to abuse. The current pilot investigation shows that agomelatine might offer the prospect of becoming a valuable addition to the pharmacological repertoire for the treatment of alcohol-dependence–associated insomnia.
Sleep Med Rev 7 6 523 2003 10.1016/S1087-0792(03)90005-0 Insomnia, alcoholism and relapse.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 공개 리포지터리에 출판본, post-print, 또는 pre-print를 셀프 아카이빙 하여 자유로운 이용이 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.